Erman ÇAKAL, Mustafa ŞAHİN, Muhammed KIZILGÜL, Mustafa ÖZBEK, Bekir UÇAN

Cyclooxygenase-2 (COX-2) gene polymorphism in patients with differentiated thyroid carcinomas in the Turkish population

Background/aim: The most common thyroid malignancies are papillary and follicular thyroid carcinomas. They account for approximately 85% 90% of all thyroid cancers. Recent studies have reported the relevance of cyclooxygenase-2 (COX-2) gene polymorphism in human carcinogenesis. The aim of this study was to investigate the relationship between thyroid carcinoma and COX2 gene polymorphism in the Turkish population. Materials and methods: We included a total of 96 differentiated thyroid cancer patients (mean age: 46.9 ± 10.3 years; 14 males, 82 females) and 83 healthy control subjects (mean age: 46.0 ± 10.6 years; 39 males, 44 females). The frequency of -765G>C, -8473T>C, and 1195A>G gene polymorphisms in the COX-2 promoter region was investigated in thyroid cancer patients and the control group using the high-resolution melting method. Results: COX-2-765G>C and COX-2-1195A>G gene polymorphisms were similar between thyroid cancer patients and the control group. There was a statistically significant difference between COX-2-8473T>C gene polymorphism in the thyroid cancer group and the control group (P = 0.012). Conclusion: The single nucleotide gene polymorphism COX-2-8473T>C might contribute to genetic susceptibility to differentiated thyroid cancer in the Turkish population.

PDF

___

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA-J Am Med Assoc 2006; 295: 2164-2167.
2. Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Maréchaud R, Niccoli-Sire P, Nocaudie M, Orgiazzi J, Schlumberger M, Wémeau JL et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004; 150: 133-139.
3. Elisei R, Molinaro E, Agate L, Bottici V, Masserini L, Ceccarelli C, Lippi F, Grasso L, Basolo F, Bevilacqua G et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocr Metab 2010; 95: 1516-1527.
4. Sadetzki S, Calderon-Margalit R, Modan B, Srivastava S, Tuttle RM. Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose externalbeam irradiation in childhood. J Clin Endocr Metab 2004; 89: 2281-2289.
5. Caudill CM, Zhu Z, Ciampi R, Stringer JR, Nikiforov YE. Dosedependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocr Metab 2005; 90: 2364-2369.
6. Xing M. BRAF mutation in thyroid cancer. Endocr-Relat Cancer 2005; 12: 245-262.
7. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V. Expression of PAX8-PPAR gamma-1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocr Metab 2002; 87: 3947-3952.
8. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPAR gamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002; 26: 1016-1023.
9. Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Multhaupt H, Atkins JP, Rosen MR, Keane W et al. Expression of RET/PTC gene as a marker for papillary thyroid carcinoma on Hashimotos thyroiditis. Laryngoscope 1997; 107: 95-100.
10. Califano D, Rizzo C, DAlessio A, Colucci-DAmato GL, Cali G, Bartoli PC, Santelli G, Vecchio G, de Francisis V. Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells. J Biol Chem 2000; 275: 19297- 19305.
11. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-9054.
12. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 3: 493-501.
13. Fosslien E. Molecular pathology of cyclooxygenase-2-cancerinduced angiogenesis. Ann Clin Lab Sci 2001; 31: 325-348.
14. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer I 1998; 90: 455-460.
15. van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002; 196: 171-179.
16. Shirahama T, Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7: 558-561.
17. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. P Natl Acad Sci USA 1992; 89: 7384-7388.
18. Smith WL, Meade EA, DeWitt DL. Interaction of PGH synthase isozymes-1 and -2 with NSAIDs. Ann NY Acad Sci 1994; 744: 50-57.
19. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and anti-tumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
20. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7: 861-867.
21. Brabender J, Park J, Metzger R, Schneider PM, Lord RV, Hölscher AH, Danenberg KD, Danenberg PV. Prognostic significance of cyclooxygenase 2 mRNA expression in nonsmall cell lung cancer. Ann Surg 2002; 235: 440-443.
22. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-635.
23. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002; 33: 708-714.
24. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastas 2002; 19: 527-534.
25. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase expression in esophageal carcinoma. Cancer Res 1999; 59: 198-204.
26. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancer, specifically adenocarcinomas. Cancer Res 1998; 58: 3761-3764.
27. Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey TJ 3rd. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocr Metab 2002; 87: 358-363.
28. Lo CY, Lam KY, Leung PP, Luk JM. High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma. Eur J Endocrinol 2005; 152: 545-550.
29. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozava T, Matsuzuka F, Matsuura N, Kuma K et al. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 2003; 42: 492-497.
30. Ji B, Liu Y, Zhang P, Wang Y, Wang G. COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. International Journal of Medical Sciences 2012; 9: 237-242.
31. Giaginis C, Alexandrou P, Delladetsima I, Karavokyros I, Danas E, Giagini A, Patsouris E, Theocharis S. Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions. Pathol Oncol Res 2016; 22: 189-196.
32. Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV. Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Modern Pathol 2005; 18: 221-227.
33. Scarpino S, Duranti E, Stoppacciaro A, Pilozzi E, Natoli G, Sciacchitano S, Luciani E, Ruco L. COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. J Pathol 2009; 218: 487- 494.
34. Zhang XM, Zhong R, Liu L, Wang Y, Yuan JX, Wang P, Sun C, Zhang Z, Song WG, Miao XP. Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population. PLoS One 2011; 6: e21894.
35. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 2009; 9: 407.
36. Balistreri CR, Caruso C, Carruba G, Miceli V, Campisi I, Listì F, Lio D, Colonna-Romano G, Candore G. A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr Pharm Design 2010; 16: 718-724.
37. Cox DG, Buring J, Hankinson SE, Hunter DJ. A polymorphism in the 3 untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res 2007; 9: R3.
38. Lim WY, Chen Y, Ali SM, Chuah KL, Eng P, Leong SS, Lim E, Lim TK, Ng AW, Poh WT et al. Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis 2011; 32: 522-529.
39. Liu CJ, Hsia TC, Wang RF, Tsai CW, Chu CC, Hang LW, Wang CH, Lee HZ, Tsai RY, Bau DT et al. Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients. Anticancer Res 2010; 30: 1195-1199.
40. Pan F, Tian J, Pan Y, Zhang Y. Lack of association of the cyclooxygenase 8473 T>C polymorphism with lung cancer: evidence from 9841 subjects. Asian Pac J Cancer P 2011; 12: 1941-1945.
41. Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippl P. The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res 2006; 12: 1392-1394.
42. Park JM, Choi JE, Chae MH, Lee WK, Cha SI, Son JW, Kim CH, Kam S, Kang YM, Jung TH et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006; 6: 70.
43. Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barretts esophagus, and esophageal adenocarcinoma. Cancer Epidem Biomar 2008; 17: 727-731.
44. Fawzy MS, Aly NM, Shalaby SM, El-Sawy WH, AbdulMaksoud RS. Cyclooxygenase-2 169C>G and 8473T>C gene polymorphisms and prostaglandin E2 level in breast cancer: a case-control study. Gene 2013; 527: 601-605.
45. Kim JG, Chae YS, Sohn SK, Moon JH, Ryoo HM, Bae SH, Kum Y, Jeon SW, Lim KH, Kang BM et al. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemoth Pharm 2009; 64: 953-960.
46. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, Zhang B, Zhao D, Yang M, Yu D et al. Cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007; 28: 1197- 1201.
47. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 565-576.
48. Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, Dong C, Shen L, Li J, Deng D et al. Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006; 130: 1975-1984.